About Shockwave medical, inc.
Shockwave Medical, Inc. is a leading cardiovascular medical device company that is revolutionizing the treatment of calcified cardiovascular disease with Intravascular Lithotripsy (IVL). The company was founded in 2009 by Dr. Todd Brinton and Daniel Hawkins, who recognized the need for a new approach to treating calcified plaque in arteries.
Calcified plaque can be a significant problem for patients with cardiovascular disease, as it can make it difficult or impossible to perform procedures such as angioplasty or stenting. Shockwave Medical's IVL technology uses sonic pressure waves to break up calcified plaque without damaging healthy tissue, making it an effective and minimally invasive alternative to traditional treatments.
The company's flagship product is the Shockwave M5 IVL System, which has been approved by regulatory agencies around the world and is used by physicians in over 30 countries. The M5 system consists of a catheter that delivers sonic pressure waves directly to the site of calcified plaque, allowing physicians to safely and effectively treat even complex cases.
In addition to its groundbreaking technology, Shockwave Medical is also committed to providing education and support for physicians using IVL. The company offers training programs and clinical support services designed to help physicians achieve optimal outcomes for their patients.
One key advantage of Shockwave Medical's IVL technology is its ability to treat multiple types of calcified lesions throughout the body. This includes not only coronary artery disease but also peripheral artery disease (PAD), which affects millions of people worldwide.
PAD occurs when arteries outside of the heart become narrowed or blocked due to buildup of fatty deposits or calcium deposits on artery walls. This can cause pain or discomfort in the legs when walking or exercising, as well as increase risk for heart attack or stroke.
Shockwave Medical's IVL technology has shown promising results in treating PAD through clinical trials such as DISRUPT PAD III and DISRUPT PAD V. These studies have demonstrated high rates of procedural success with minimal complications, making IVL an attractive option for patients with this condition.
Overall, Shockwave Medical represents an exciting new frontier in cardiovascular medicine that has already made a significant impact on patient care around the world. With continued innovation and investment in research and development, this pioneering company will undoubtedly continue changing lives for years to come.